What does IATREION do?

IATREION is a general practice in Gent. Private Limited, started on 18 April 2001, 1 establishment.

What is the address of IATREION?

The registered office of IATREION is located at Dendermondsesteenweg 449, 9040 Gent.

Is IATREION still active?

Yes. According to the CBE (29 October 2026) IATREION is active, legal situation “Normale toestand”, started on 18 April 2001.

Is IATREION registered on Peppol?

Yes, IATREION is registered on the Peppol network with ID 0208:0474603083.

What is the enterprise number of IATREION?

The enterprise number of IATREION is BE0474603083.

When was IATREION founded?

IATREION was founded on 18 April 2001.

Who are the directors of IATREION?

According to the 2025 annual accounts, the directors of IATREION are: Radiology Partners Europe BV, Niels Favoreel.

Is IATREION a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 April 2001; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did IATREION make in 2025?

IATREION posted a profit after taxes of € 160,074 in financial year 2025.

What is the revenue of IATREION?

As a small company, IATREION is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 383,750.

How much does an employee at IATREION earn?

The average wage cost per full-time employee at IATREION was € 48,900 in 2025: staff costs of € 122,263 for 2.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does IATREION have?

According to the 2025 annual accounts, IATREION has 2.5 full-time equivalents (FTE).

IATREION (Private Limited) - Gent - BE0474603083

Dossier IATREION, printed on 29 October 2026 from databakkes.be/en/0474603083/iatreion. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 2.8 to 2.5.
Board fully replaced NBB

No director from three years ago is still active according to annual account 2025.

Financials

Financial year 2025

IATREION from Gent, company number BE0474603083, closed financial year 2025 with a result of € 160,074 after tax. For that financial year IATREION recorded a gross margin of € 383,750 and equity of € 349,585. Compared with financial year 2024, the result moved from € 116,146 to € 160,074. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 27, 2026.

What it is worth Growing

€ 349,585

▲ 84% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 160,074

▲ 38% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 315,741

▲ 62% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 333,353.

People and assets in 2025

Full-time equivalents

2.5

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 122,263

▲ 5% vs 2024

€ 48,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 11,853

▼ 73% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 5,234

▼ 93% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 37,266

▲ € 29,822 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 22,896

▲ 46% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 326,111 Gross margin 2022: € 326,111 First fiscal year in the series	€ 353,594 Gross margin 2023: € 353,594 ▲ 8% vs 2022 (€ 326,111) Favourable step	€ 334,572 Gross margin 2024: € 334,572 ▼ 5% vs 2023 (€ 353,594) Unfavourable step	€ 383,750 Gross margin 2025: € 383,750 ▲ 15% vs 2024 (€ 334,572) Favourable step	▲ 15%
Profit after taxes	€ 116,375 Profit after taxes 2022: € 116,375 First fiscal year in the series	€ 123,947 Profit after taxes 2023: € 123,947 ▲ 7% vs 2022 (€ 116,375) Favourable step	€ 116,146 Profit after taxes 2024: € 116,146 ▼ 6% vs 2023 (€ 123,947) Unfavourable step	€ 160,074 Profit after taxes 2025: € 160,074 ▲ 38% vs 2024 (€ 116,146) Favourable step	▲ 38%
Equity	€ 152,518 Equity 2022: € 152,518 First fiscal year in the series	€ 152,565 Equity 2023: € 152,565 Unchanged (€ 152,518) Favourable step	€ 189,511 Equity 2024: € 189,511 ▲ 24% vs 2023 (€ 152,565) Favourable step	€ 349,585 Equity 2025: € 349,585 ▲ 84% vs 2024 (€ 189,511) Favourable step	▲ 84%
Total debts	€ 266,766 Total debts 2022: € 266,766 First fiscal year in the series	€ 244,169 Total debts 2023: € 244,169 ▼ 8% vs 2022 (€ 266,766) Favourable step	€ 160,271 Total debts 2024: € 160,271 ▼ 34% vs 2023 (€ 244,169) Favourable step	€ 65,396 Total debts 2025: € 65,396 ▼ 59% vs 2024 (€ 160,271) Favourable step	▼ 59%
Cash	€ 156,590 Cash 2022: € 156,590 First fiscal year in the series	€ 207,645 Cash 2023: € 207,645 ▲ 33% vs 2022 (€ 156,590) Favourable step	€ 195,217 Cash 2024: € 195,217 ▼ 6% vs 2023 (€ 207,645) Unfavourable step	€ 315,741 Cash 2025: € 315,741 ▲ 62% vs 2024 (€ 195,217) Favourable step	▲ 62%
Retained profit	€ 136,286 Retained profit 2022: € 136,286 First fiscal year in the series	€ 136,333 Retained profit 2023: € 136,333 Unchanged (€ 136,286) Favourable step	€ 173,279 Retained profit 2024: € 173,279 ▲ 27% vs 2023 (€ 136,333) Favourable step	€ 333,353 Retained profit 2025: € 333,353 ▲ 92% vs 2024 (€ 173,279) Favourable step	▲ 92%
Dividend	€ 91,400 Dividend 2022: € 91,400 First fiscal year in the series	€ 123,900 Dividend 2023: € 123,900 ▲ 36% vs 2022 (€ 91,400) Unchanged	€ 79,200 Dividend 2024: € 79,200 ▼ 36% vs 2023 (€ 123,900) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 79,200) Unchanged	▼ 100%
Bank debt	€ 177,557 Bank debt 2022: € 177,557 First fiscal year in the series	€ 129,262 Bank debt 2023: € 129,262 ▼ 27% vs 2022 (€ 177,557) Favourable step	€ 80,491 Bank debt 2024: € 80,491 ▼ 38% vs 2023 (€ 129,262) Favourable step	€ 5,234 Bank debt 2025: € 5,234 ▼ 93% vs 2024 (€ 80,491) Favourable step	▼ 93%
Balance sheet total	€ 419,284 Balance sheet total 2022: € 419,284 First fiscal year in the series	€ 396,734 Balance sheet total 2023: € 396,734 ▼ 5% vs 2022 (€ 419,284) Unchanged	€ 349,782 Balance sheet total 2024: € 349,782 ▼ 12% vs 2023 (€ 396,734) Unchanged	€ 414,980 Balance sheet total 2025: € 414,980 ▲ 19% vs 2024 (€ 349,782) Unchanged	▲ 19%
Employees (FTE)	2.8 Employees (FTE) 2022: 2.8 First fiscal year in the series	2.8 Employees (FTE) 2023: 2.8 Unchanged (2.8) Unchanged	2.6 Employees (FTE) 2024: 2.6 ▼ 0.2 vs 2023 (2.8) Unchanged	2.5 Employees (FTE) 2025: 2.5 ▼ 0.1 vs 2024 (2.6) Unchanged	▼ 0.1

Key figures of IATREION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to IATREION?

What happened at IATREION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 27, 2026 New annual accounts for financial year 2025: profit of € 160,074 (▲ 38% vs 2024). Source: NBB ↗
2025 Radiology Partners Europe BV became a director. NBB
2025 Niels Favoreel stepped down as director. NBB
2022 Niels Favoreel became a director. NBB
Apr 18, 2001 Start of the company according to the CBE. KBO
Apr 5, 2001 New establishment in Aalter. KBO

In short

From € 116,375 profit in 2022 to € 160,074 profit in 2025.

Paid € 176,414 in corporate taxes since 2022.

Best year ever: 2025, with € 160,074 profit.

On average € 153,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Radiology Partners Europe

RX FAVOREEL 100%

The stake of RX FAVOREEL comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

IATREION

Behind IATREION is Radiology Partners Europe BV. The shares are held by Radiology Partners Europe and RX FAVOREEL (100%).

Directors

According to the 2025 annual accounts

Radiology Partners Europe BV

Director · represented by Forton Francis

Also active at: CENTRE RX DE WAVRE, IMMO X, RADIOLOGIE DR. HANS JASPERS, IMAGERIE MEDICALE DOCTEUR BERSOU, Radiologie Dr. Favoreel, RX Braekeveld MB, Radiologiepraktijk, Centre d'Imagerie Médicale de Gembloux +3 more

since 2025

Niels Favoreel

Director

Also active at: Radiologie Dr. Favoreel, RX FAVOREEL, IMMORAD, RX Mariakerke

since 2022 · until 2025

Shareholders

Radiology Partners Europe

RX FAVOREEL

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Dendermondsesteenweg 449

9040 Gent

2.143.488.677

Lostraat 20

9880 Aalter

Active since 5 April 2001

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Radiologie Dr. Favoreel same network

€ 750,945 gross margin · 2026

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0474.603.083

VAT number

BE 0474.603.083

Registered office

Dendermondsesteenweg 449, 9040 Gent

Names & denominations

IATREION

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

18 April 2001

Peppol

Active · Active since 21 Oct 2026

Activities · NACE

Activiteiten van huisartspraktijken

Medische praktijken

Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗

IATREION

Warning lights

Financials

What happened to IATREION?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions